Get started
Author

Hayati Arvas

Observed names: H. Arvas, HAYATİ ARVAS
Institution: Dicle University
Observed institution: Dicle University
ORCID: 0000-0003-2215-5567
Observed ORCID: 0000-0003-2215-5567
OpenAlex ID: A5092098183
Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group
2025 · Nadiye Sever, Fatih Şimşek, et al. · Journal of Clinical Medicine · 19
Clinical Utility of Pan-Immune Inflammation Value (PIV) in Predicting Prognosis of Endometrial Cancer
2025 · Nurhan Onal Kalkan, Zuhat Urakcı, et al. · Journal of Clinical Medicine · 12
PDF
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
2025 · Yasin Sezgin, Oğur Karhan, et al. · Scientific Reports · 9
PDF
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy
2024 · Yusuf Ilhan, Gokhan Ucar, et al. · Expert Opinion on Pharmacotherapy · 8
Impact of renin–angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non–small cell lung cancer
2026 · Emel Mutlu Ozkan, Ibrahim Karadağ, et al. · Expert Review of Anticancer Therapy · 3
Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab
2026 · Gözde Ağdaş, Duygu Bayir, et al. · Scientific Reports · 2
PDF
Bridging East and West: Real-World Clinicogenomic Landscape of Metastatic NSCLC in Türkiye
2025 · Kübra Canaslan, Emre Eken, et al. · Genes · 2
PDF
Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study
2024 · Ogur Karhan, Serdar İleri, et al. · Oncology · 2
Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients
2026 · Muhammet Cengiz, Oktay Bozkurt, et al. · Scientific Reports · 1
PDF
Serum Carcinoembryonic Antigen Levels Across Molecular Subtypes and Their Clinical and Prognostic Implications in Metastatic Non-Small Cell Lung Cancer
2026 · Ali Aytac, Bilgin Demir, et al. · Medicina · 1
PDF
Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study
2026 · Mustafa Ersoy, Umut Kefeli, et al. · Frontiers in Immunology · 1
PDF
Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)
2026 · Sercan On, Selin Cebeci, et al. · Cancers · 1
PDF
Resection and pathological response after neoadjuvant nivolumab plus chemotherapy for lung cancer in a Turkish Oncology Group (TOG) real-world study
2026 · Erdem Sünger, Bahadır Köylü, et al. · Research Square
PDF
Real-World Outcomes of Second-Line Chemotherapy in Metastatic Urothelial Carcinoma
2026 · İlkay Çıtakkul, Hayati Arvas, et al. · Current Oncology
546P HER2-low status in resectable gastric cancer: An underrecognized subgroup with distinct survival outcomes
2026 · I. Deliktas Onur, H.G. Frat, et al. · Annals of Oncology
PDF
559eP Perioperative versus adjuvant chemotherapy in gastric cancer: A retrospective cohort comparison of treatment effectiveness
2026 · I. Deliktas Onur, H.G. Frat, et al. · Annals of Oncology
PDF
Real-world outcomes of trifluridine/tipiracil with or without bevacizumab in refractory metastatic colorectal cancer: a multicenter cohort study from Turkey
2026 · Selami Bayram, Bahadir Koylu, et al. · Discover Oncology
Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab
2026 · Erdem Kolemen, Kazım Uygun, et al. · Discover Oncology
Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
2026 · Yasin Sezgin, Oğur Karhan, et al. · Scientific Reports
PDF
Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group
2026 · Sedat Yıldız, Hacer Demir, et al. · Journal of Clinical Medicine
PDF
The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer
2026 · Muhammet Cengiz, Oktay Bozkurt, et al. · Discover Oncology
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group
2026 · Salih Tunbekici, Hamit Bal, et al. · Clinical & Translational Oncology
Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer
2026 · Ayse Nuransoy Cengiz, Oktay Bozkurt, et al. · Journal of Clinical Medicine
PDF
Gene Therapy in Oncology
2024 · Hayati Arvas, Zuhat Urakci
Diffuse Cerebral Infarction Due to Massive Thromboembolism in A Young Male Patient With ALK-Positive Non-Small Cell Lung Cancer: Is the ALK Rearrangement Related to Thrombosis?
2023 · Zuhat Urakci, Sezai Tunç, et al. · Clinical Case Reports and Studies
PDF
Works count: 26
Citation count: 61
H-index: 4
I10-index: 2
Year
Topic
Type